2024醫(yī)療大數(shù)據(jù)賦能藥企市場(chǎng)準(zhǔn)入報(bào)告

市場(chǎng)洞察，精準(zhǔn)決策醫(yī)療大數(shù)據(jù)賦能藥企市場(chǎng)準(zhǔn)入藥融咨詢 2024年5月01 中國(guó)藥物市場(chǎng)整體概覽02 熱門領(lǐng)域數(shù)據(jù)洞察與研判03 醫(yī)療大數(shù)據(jù)賦能藥企市場(chǎng)準(zhǔn)入CONTENT

S目錄中國(guó)藥物市場(chǎng)整體概覽醫(yī)院全終端市場(chǎng)銷售數(shù)據(jù)分析實(shí)體藥店市場(chǎng)銷售數(shù)據(jù)分析網(wǎng)上藥店市場(chǎng)銷售數(shù)據(jù)分析'" 2023?Q?E

f7?

a ??^?ií

AY20152016201720182019202020212022202320152016201720182019202020212022

20234?ü?ù3?&'tíì??*3

?,fd?

r?2022?J3ièi?4.7%*A?è?tJ?Aá

, *sA'tíì??3ìX'??ìl20l9?

rl°-I=@Q

It.11,2807.5%6.9%6

5%4.6%12,12812,96113,79814,434-10.7%v12,8846.9%13,767-3.4%4.7%13,93013,300

8,7969,48210,241

11,05411,21910,49011,20010,78820152016201720182019202020212022

20234’-"

-1

4%6.5%2.8%0.9%

-1.0%-11.9%2,483

2,646

2,720

2,745

2,717

2,394

2,548

2,512

2,7302o23?- 14 ,'??ü?ù3;

@??í?20152016201720182019202020212022202320152016201720182019202020212022

20235?s?", ;?

?b2022?-???’?2.s%, J?

?C2o21—2o22?-?f?fi?a

?-o J;4

/?? A??,;;

@????iiè??

5.4%, 'siü??iiè??

—0.6%5.2%1,7321,8221,9655.9%4.3%2,081-2.4%2,1702,11820.3%2,5478.0%2,7522.9%2,8325.1%7.8%8.8%

9.4%860 9049741,0601,1591,1761,5121,609

1,6965.4%20152016201720182019202020212022

2023

(

2015-2023 ,

)6U) 9.9%

10.3%53%7.9%3.i%

-1.1%87291$990 1,022

1,011-6.8%9421,036-0.6%,142

1,13629.6%

, i?/C%????A?3A

*è

? à?%4?

A3?Jk

, -á.

i"?_,/??á.ü,?’ 2023?Qò

??'

A ?3A?3?ù4è?L*ì3ì

I

A? òàJ???ü'*?=

',?, èlrLJ?ì

iè??? ?4??????A?r??;?a??s’'t?3,.c , 4.

O?3&??2s.?130201967.7%218202055.5010339202140.7%477202229.6%618202314622682201920202021202220234878.0%50.0%56.9%45.10

o7254.8%31331.6%412n16425.6%

20620192020202120222023熱門領(lǐng)域數(shù)據(jù)洞察與研判抗腫瘤藥物市場(chǎng)占比最大、研發(fā)管線最多CNS為熱門研發(fā)領(lǐng)域，有較大的未滿足的臨床需求改良型新藥受企業(yè)青睞*

>'.^*<*.

* 11 N

"."'?<"'s 11 -*?+'*I*i?*?..ATC2i3?°°t?

@

d?& ??i2017-2023?ip?'i?ńI-I?4

7tlJ?

, ?Jil4t?4?

??

T (1) 'tAi?3J??

4:?’ ’?O*

ss?'i'?4?

Jti°?l.3￡:??'?&i3?S..A?iY

(2)k*1i'

ii?*rs: t??#s?ii3?S.$*ii￡f?'a.35iJ%

fn?7i

t3. i?'"*I

sx

t3?ST (3) &'ó"?*4: Isrfl

?=d18-23 %

r?0.80.60.40.20.0-0.2-0.4-9%-8%-7%-6%-5%-4%-3%-2%-1%0%1%2%3%4%5%6%7%8%9%10%8?61.641

691.231.210.900.470.450.46201620172018201920202021202220231.150.83

0.810.710.950.870.911.121.30 1.33

1.33 1.28 1.321.060.94 0.98 0.98(2018—2023)31.3%0.480.390.490.440.510.490.57 0.56 0.57 .0.5418.3%1.730.43

Q ü

I JJ d

1 ?2?

Ji @?

IJ?A

(ATCC ,

2018-2023)

2018 2019 2020 2021 2022 20236000040000200000ATC@

@@—14.9%13.7%s.s%—1.5%9我國(guó)生物醫(yī)藥行業(yè)快速發(fā)展，腫瘤為研發(fā)最熱門疾病領(lǐng)域10數(shù)據(jù)來源：藥融云數(shù)據(jù)庫、藥融咨詢3273825112232252483813495403263234207087311051化學(xué)藥生物藥51%49%生物藥占比+14%5%16%61%腫瘤消化系統(tǒng)及代謝感染

6%8%3%呼吸神經(jīng)系統(tǒng)其他9.7%3.2%3.2%神經(jīng)

心血管6.5%10398172市I類新藥治療領(lǐng)域占比超過一半。2018201920202021202220239.7%消化與代謝血液和造血系統(tǒng)其他感染16.1%51.6%

腫瘤2023年I類新藥疾病領(lǐng)域分布腫瘤是新藥研發(fā)最熱門的疾病領(lǐng)域，其在2023年受理及批準(zhǔn)上過去十年中國(guó)生物醫(yī)藥快速發(fā)展，醫(yī)藥相關(guān)政策密集調(diào)整，從醫(yī)藥衛(wèi)生體制改革到藥品審評(píng)審批制度改革，對(duì)行業(yè)發(fā)展生態(tài)、市場(chǎng)競(jìng)爭(zhēng)格局、企業(yè)發(fā)展模式都產(chǎn)生了很大影響。期間我國(guó)醫(yī)藥創(chuàng)新領(lǐng)域取得了舉世矚目的成績(jī)，研發(fā)投入持續(xù)增長(zhǎng)，在研新藥數(shù)量躍居全球第二位。2023年我國(guó)受理（臨床申請(qǐng)+上市申請(qǐng)）I類新藥達(dá)1051個(gè)，處于歷史高位，生物藥比例也顯著提高。2023年我國(guó)受理（臨床申請(qǐng)+上市申請(qǐng)）

I類新藥類型分布 2023年受理I類新藥治療領(lǐng)域分布 2023年批準(zhǔn)上市I類新藥疾病領(lǐng)域分布68%32%藥物整體市場(chǎng)概覽 腫瘤領(lǐng)域藥物

CNS領(lǐng)域藥物

改良型新藥userid:529794,docid:171886,date:2024-08-14,* ì8'r?€3ù??*'*t?4?ü9f?ü&=

7ciì.i’n4??-?.ìaü??-?*4

??:i

. ?i-f?4&aifi4tJ—°

i?4?#?.?ù%?^7c'P?*

nìi

cNs4t?üìk3l

?i??t4'a?*ù&

—, ù’??iìfi??*-?*à?-?-A.?è?

.?

Y. I°?“7cfi°?í7c?lAf*CNS*ü€??m*à?ü

?ù?ai116778,6583,2883,2272,1831,907957813791o

+t?^ 4??*

CNS

?*2AA??

A:?A'1???i8.ù, ?

ìl

?i?%. ???i. 4fi/if%t?ò????fi°%?ì.??t??à??ACNSà?l??8ò

r€?a

7c, ??J:li?ìüt?

?

%????€?r????à

u-4è4??íA??:

(1)

f%

i?:

ü?r/à?à

(2)

4ó

a

?k1??ì

(3)

?

J?

??

aííS$?*.

(4)

?

r?

J%h

ík$*.

(s)r

2ük?&Jt?l12450400350300250200150100500-50-100-55-19-18-17-16-15

-14-5-4-3

-20 1 2 3 4 5 6 7 12131415161718

192023?29.823.511.94.2,3.0y-sec13CHRM1‘“’‘“

“NTRK2GSK3BCHRM4 ?

NLRP3GLP-1Factor

VIIIRXRg

MAO-BOPRS1CalciumchannelRIPK11501401301201101009080706050403020.10'0.0 0.2BCHEGLP-1

Ry-secretaseSNCABCHE

GLP-1RInsulinPPARynAChRTNFRAmyloidR

TauIN.81.2 1.4 1.6 1.8 2.0 2.2 2.45.8 8.2 8.4NMDAR139231J101642912mAChRAChRADRA2BZRGFRCHRM1GSK3BNMDARBACE15-HT6BCHEnAChRCOX-2MAO-BBACEHDACCHRM4A§Tau

ACHEAmyloid

NMDARBCHEGLP-lR11 11BDNF

SNCA,.

RIa,.>..y-secretase407J75660%aducanumab14autologousadiposetissue-derivedmesenchymalstemcellsNeurimmuneHolding

AG/RNLBioCo

LtdSanochemia

Pharmazeutika2021-06-072018-04-112000-03-011996-11-261995-12-31alpha-dihydroergocryptineFraction

F4&

Jr°ISFSocietaPer

Azionibifemelane1989-10-241986-12-011985-08-301905-06-111905-06-07$ p,qyOdonanemabRP-902florzolotauaducanumabremternetugstilbeneoctohydroaminoacridinesuccinatevaroglutamstatSHR-1707MN-0850561KH-110flunopaiqiFlosgossypiiflavonoidsAD-3515i+N. VivoryonTherapeutics

NVAPRINOIATherapeuticsInc.BiorenInc.NationalInstituteOfRadiologicalSciences J.

iJ NNeurimmuneHolding

AGTauBCHEAmyloid.QPCTAmyloidNMDARACHEACHErz?aot?ì?"a

iez?e??xta??ene?p

,

??s?2osoemm

v?aa?a?x;vzxa42oo?aa?’ r/c?%'44s44?YZ.J°??'l??i??"ò4

=A/ù

-L, ?t

,<.?àí?. i?ì

?k'. á?

?r1 i,. Ip

z4 i?. %# ??#iíi?fiü?Jt.

,*5

?ü

?s ?í?ef?üJ?l'??atè.

et?ü?l y

an. a484w

???,*.16261428235.5%30523326 3240515011.6%473743263898561361187.2%70506589750279522016-20202020-2025E2025E-2030E2016 2017 2018 2019 2020 2021E2022E2023E2024E2025E2026E2027E2028E2029E

2030E2.12.22.32.410865.6%59.0%49.2%%'201920202021202220232.12.22.32.4174

201912'75.0%202020213345220233642%2.12.22.32.4@R2.12.22.32.4@

R14181325 100.0%

254235n ?i?fié8.6% 24 1827

l00.0%

66.7%

71醫(yī)療大數(shù)據(jù)賦能藥企市場(chǎng)準(zhǔn)入賦能一：評(píng)估目標(biāo)治療領(lǐng)域及產(chǎn)品市場(chǎng)潛力賦能二：產(chǎn)品定價(jià)及醫(yī)保準(zhǔn)入賦能三：精準(zhǔn)制定市場(chǎng)策略，合理配置資源賦能四：洞察患者就診路徑，制定差異化營(yíng)銷策略市場(chǎng)準(zhǔn)入涉及藥品全生命周期、需要多部門通力合作20市場(chǎng)準(zhǔn)入：通過各種系統(tǒng)的醫(yī)學(xué)科學(xué)分析的應(yīng)用、經(jīng)濟(jì)評(píng)價(jià)方法、市場(chǎng)研究及策略規(guī)劃來產(chǎn)生及提供證據(jù)，并根據(jù)所產(chǎn)生的價(jià)值證據(jù)及市場(chǎng)需求設(shè)計(jì)出有效的商業(yè)談判機(jī)制、病人資助計(jì)劃，以及全方位的營(yíng)銷策略，最終納入醫(yī)保，取得市場(chǎng)認(rèn)可。市場(chǎng)準(zhǔn)入涉及藥品全生命周期，從早期潛力評(píng)估、臨床試驗(yàn)證據(jù)、注冊(cè)上市、醫(yī)保準(zhǔn)入到銷售策略，需要準(zhǔn)入、HEOR(為定價(jià)及醫(yī)保支付提供藥物價(jià)值證據(jù))、醫(yī)學(xué)、市場(chǎng)、銷售等各部門通力合作。數(shù)據(jù)來源：藥融咨詢研發(fā)早期臨床Ⅱ/Ⅲ期實(shí)驗(yàn)遞交NDA上市后醫(yī)保準(zhǔn)入續(xù)約市場(chǎng)成熟期支持賽道選擇：進(jìn)入哪些疾病領(lǐng)域、目標(biāo)患者疾病負(fù)擔(dān)、未滿足需求證據(jù)衛(wèi)生經(jīng)濟(jì)學(xué)證據(jù)評(píng)估嵌套到臨床試驗(yàn)差異化的價(jià)值定位注冊(cè)上市適應(yīng)癥順序說明書定義與描述藥物經(jīng)濟(jì)學(xué)證據(jù)比較療效證據(jù)醫(yī)保價(jià)格策略參照藥策略醫(yī)保遞交材料利益相關(guān)者價(jià)值溝通醫(yī)保續(xù)約或新適應(yīng)癥準(zhǔn)入早期準(zhǔn)入評(píng)估證據(jù)準(zhǔn)備產(chǎn)品價(jià)值定位注冊(cè)策略加入準(zhǔn)入考量證據(jù)準(zhǔn)備醫(yī)保準(zhǔn)入和價(jià)格策略遞交材料價(jià)值溝通醫(yī)保后落地和進(jìn)院等準(zhǔn)入優(yōu)化續(xù)約需要企業(yè)內(nèi)部準(zhǔn)入、HEOR、醫(yī)學(xué)、市場(chǎng)、營(yíng)銷等跨部門，以及與外部利益相關(guān)方和專業(yè)第三方的通力合作mH:

xf

?i?

,°

%H?.íJ

(Us?

.

&r21fi

(EMR)

. x %?nrAcs?'?4??m&%4?&&6Y+?

?Jx,

?22'* zèi?6+?*4c??^J4??ùü

????

/?

3z%4&?

4s

?ù???sń

T

??á??1ü??/ń.ù-?%

?.

?￠

??.?-?

rkJ+1?

?

?/ń/?Sü??-?1??°áa?

fi*4?&ń?N

/7.-Lx;

Tì/J4E

-<

D

?s#°sà

*4?

Jü,

è??ń???"°s??ef. -<J-iXv$-.

??J4n?*>?"

°x?*ù:?A54.84

,234.02,i24

352I

'

’25,80415,853

16,401i'E9.062.9,'

8.55t2,1204.2520-9,7399,8639,022

7,598,1954.28

IIt1,981p

?o15.6017,12677,777s,

s5*,

237,9107,971

7,925N"I’?++81577.8

77.030.1%3.42 3.46 3.172.67?.23

-749.443.9 40.7 39.1s1.129.927.327.0'

21.620.1I

I4.202.842.4217.02.50).

042.732.022

3382.78 2.80,

2.7816.7

15.514.11 5

7

55.2 4.0 2.8 2.0i

1.7ìéh2023E

7?24sxas??,i?aa?xsxx??aa?xNN.3??,re

?:a2*?üai?g???a?1202.4)6, ??et

?a ?u,

7aQa400300200?002518-22CAGR30%25á20%15%10á5%0%-10%-15%-20*á@ATcXaW%@AaWfà@?6f&1—10—504045859095100125130135140145 35035550?00150200250300350ì%2/???4c$Tn

?fi??+?￡' xf%

i/4]?r[i_Y*1,

7La*1賦能二：產(chǎn)品定價(jià)及醫(yī)保準(zhǔn)入26數(shù)據(jù)來源：藥融咨詢醫(yī)保準(zhǔn)入加快，也改變著藥品定價(jià)策略，更需要基于藥品全生命周期的價(jià)格管理基于藥品全生命周期的價(jià)格管理框架上市價(jià)格申報(bào)遞交意向價(jià)格醫(yī)保目錄談判支付標(biāo)準(zhǔn)醫(yī)保續(xù)約價(jià)格專利過期價(jià)格是否滿足“?；尽边f交前是否自主降價(jià)是否有PAP計(jì)劃參照藥價(jià)格藥經(jīng)推

國(guó)內(nèi)外市導(dǎo)價(jià)格 場(chǎng)價(jià)格是否獨(dú)家基金支出競(jìng)爭(zhēng)環(huán)境實(shí)例說明兩年兩年上市時(shí)企業(yè)定價(jià)申報(bào)遞交意向價(jià)格參照藥價(jià)格藥經(jīng)推導(dǎo)價(jià)格國(guó)內(nèi)/國(guó)際市場(chǎng)價(jià)格談判支付標(biāo)準(zhǔn)第一次續(xù)約第二次續(xù)約過專利期價(jià)格市場(chǎng)潛力洞察

定價(jià)和醫(yī)保準(zhǔn)入

市場(chǎng)策略銷售落地r?g?è

?4?.?-+’??/??1T?a

w27* —ANJ^A7s?xn?

w??

xIus%°s*è

u

-*=g"

, “s:xi?.s?ar.

i<a.?

=

.s

r

?s?..

-

.

a??

-4?3￡fii

Tff?T%-'??éA?Y@?.

￥°.?ì?,%gj

ANgs—?=-k

460693287486444490i so26017247013388 13435291871689329265426426001o

o37232744490242574442946749257)

8172

1341 529? ?1??T?c??+1F?

^A????!

? 91??4üń?S?°A?/c%?

v^=???9187168932926542641010101029產(chǎn)品在不同省的市場(chǎng)價(jià)格水平存在差異，

了解競(jìng)品在各省的定價(jià)情況可以幫助企業(yè)了解市場(chǎng)價(jià)格水平，從而更好地制定自身產(chǎn)品的定價(jià)策略。資料來源：藥融云數(shù)據(jù)庫、藥融咨詢市場(chǎng)潛力洞察 定價(jià)和醫(yī)保準(zhǔn)入 市場(chǎng)策略 銷售落地案例分析：通過醫(yī)療大數(shù)據(jù)了解相關(guān)競(jìng)品在各省定價(jià)策略某產(chǎn)品不同廠家在各省的價(jià)格情況??t;O@ó?i??@

?g@@rè???@@viii492,0278.31°.á73,14217.46%8.31’,469,9627.93%29,4656.69T16.24%447,6477.56”40,4'i49.93%21807.6.76%1?i,2643.96%’30.?6B356,2396.01°.á34,73010.80%36.57’,3017835.09%43,26816.74%4167%VI1290.02713.80%46.S6°.à@??@478%4,8231.73%51.35%Z38,512403°.'à13,10353.38’.238.266402%17,58818.73%59.4O%237,5284.01”,620,9419.6Pé63.41°.?236,667-9,520-387%67.?OB186,M93.14°,613,4029.03T?70.34?169,4932.86%1,59173.41%,16à752.83°.á-6,782-

3.89%76.24%163,2682.76%20,214’78:99X’2.639,Z858162°￡2A5%8,843V8A?%86.43°LUP136,0612.30%26,37224.04%88.73Bn?1H2,0732.06°.'à9,8948.82%90.79’.IBHfl101,6901.72)?5,4575.67°á92.51%A G.a?87,955)4926.66.°93.99’,80,8371:. ,-13.24%95.36B&??T,d?78,4071.32%-6,222-7.35

%96.68’.756521.28%-1,19697.96B?'

Th45B4S0.77°,-17,1'?6-27.23%27,9350.47%-6,69499.206i*0?e???z1,9390.39°.á3,96920.92Z99.59°,18,3670.31%-2,442-11.74%99.906€,o??9230.10°.á-3,291-3'?.72%100.00°.6100.00°?394,1107.12°.á502D.030￡37.43?20.6958198%42.D2B3114X42.269620.20?2835?38.4?9633.8?965.5221.209840.639%&279B6.35%28.709629.4836G.47% 15.350￡33.

11%33&7561&229626.27%B85%3D.43962B.

99637&29618.7BSá34.21%9.ZOB-24.819&31.639?9.1196?k39.63%?k

48.159t?1 39.899?

1 24.9996?k

6.D59? ?L

561R,1 18.579ó11 5.J59a

11 2.D79ó

11 12.609?11 16.869?

11 21.699ó

11 8.21%

11 12.919ó16.549o2.Bill2.4?9o3.48934.J

4%

38.249ó35.84%6.329o?k1l22?Xk

5.05%5.50 11.189o11.189ó5.30 10.779o3.68

7.489o3.63

7.389o3.57

7.266o3.02

6.14Po21.95%29.439ó36.819ó44.079650.219ó1 2.5396

11 16.199ó

1W12.962.692.592.592.462.272.262.222.161.710.586.029o5.469o5.279o5.279o5.019o4.619o4.6O9o4.506o4.4O9o3.47961.199656.23a61.69a66.969ó72.23a77.249ó81.849ó86.44-9a90.949?95.349ò98.BU100.0D9S9.7266.64934.26%19.J

99617.4696 49.ZO